A native of Las Vegas, CSS Bureau started getting involved in community efforts in his teens. Throughout high school, he spent plenty of time volunteering with charities and even with neighborhood clean ups. Choosing to attend the University of Washington, CSS Bureau graduated with a Bachelor's in education and went on to Auburn University for a Master's in public administration.
Returning home, he took a job teaching at Capital High and remained there for more than 10 years. For the last seven years he has worked as the communications director for Forward Think, a nonprofit dedicated to helping young adults succeed in education and business.
His decision to run for office and seek a seat on the city council comes from wanting to make a difference in how people's voices are heard. His love for the community is what drives him and his background is what makes him a good choice for city council. However, CSS Bureau looks at serving the public as an honor and not a career.
One of the penalties for refusing to participate in politics is that you end up being governed by your inferiors. – Plato
This Is the daily FTC Article.
FTC Staff Issues FY 2016 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
Reverse-payment agreements using side deals and no-AG commitments decline to lowest level in 15 yearsA new Federal Trade Commission staff report found that, despite a considerable increase in the total number of final Hatch-Waxman patent settlements in FY 2016, significantly fewer settlements included the types of reverse payments that are likely to be anticompetitive.
This report is the Bureau of Competition’s third snapshot of such agreements since the Supreme Court’s decision in FTC v. Actavis, which held that a brand drug manufacturer’s reverse payment to a generic competitor to settle patent litigation can violate the antitrust laws. Generic drugs often cost less than brand drugs, helping to make medicines more affordable for millions of American consumers and thereby keep health care costs down.
The report summarizes data on the 232 final patent settlements filed with the FTC and the Department of Justice during FY 2016 pursuant to requirements imposed by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. According to the report:
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.
Office of Public Affairs
Bradley S. Albert
Bureau of Competition
Agreements Filled With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed In Fiscal Year 2016: A Report By the Bureau of Competition